Raymond James & Associates Biomarin Pharmaceutical Inc Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Raymond James & Associates holds 58,892 shares of BMRN stock, worth $3.08 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58,892
Previous 62,884
6.35%
Holding current value
$3.08 Million
Previous $5.18 Million
20.05%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding BMRN
# of Institutions
679Shares Held
185MCall Options Held
1.31MPut Options Held
1.1M-
Black Rock Inc. New York, NY22.7MShares$1.19 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$994 Million0.02% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$825 Million0.71% of portfolio
-
Dodge & Cox San Francisco, CA15.1MShares$790 Million0.5% of portfolio
-
Viking Global Investors LP12.3MShares$643 Million2.14% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $9.72B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...